Text Size

The Effects of Riboflavin/ Ultraviolet-A Corneal Cross-linking on the Signs and Symptoms of Bullous Keratopathy (C3R)

This study has been completed.
Sponsor:
Information provided by:
Mashhad University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT01106274
First received: April 16, 2010
Last updated: NA
Last verified: October 2008
History: No changes posted
  Purpose

Recently, riboflavin (0.1%) and ultraviolet-A (UVA) collagen cross-linking (C3R) has shown potential to improve the signs and symptoms of bullous keratopathy .The objective of this study is to demonstrate the effects of C3R to treat bullous keratopathy.


Condition Intervention
Bullous Keratopathy
 Radiation: ultraviolet-A

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Study of the Effects of Riboflavin/ Ultraviolet-A Corneal Cross-linking

Resource links provided by NLM:

Drug Information available for: Riboflavin
U.S. FDA Resources

Further study details as provided by Mashhad University of Medical Sciences:

Enrollment: 20
Study Start Date: November 2008
Study Completion Date: September 2009
Intervention Details:
    Radiation: ultraviolet-A
    Corneal cross linking (C3R) with riboflavin and ultraviolet-A (UVA, 370 nm, 3mW/cm2) for 30 min
  Eligibility

Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with bollous keratopathy

Exclusion Criteria:

  • corneal scarring or contemporary eye disease affecting VA were excluded.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01106274     History of Changes
Other Study ID Numbers: MUMS-88191
Study First Received: April 16, 2010
Last Updated: April 16, 2010
Health Authority: Iran: Ethics Committee

Additional relevant MeSH terms:
Corneal Edema
Corneal Diseases
Eye Diseases
Riboflavin
Photosensitizing Agents
Radiation-Sensitizing Agents
Physiological Effects of Drugs
 Pharmacologic Actions
Dermatologic Agents
Therapeutic Uses
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances

ClinicalTrials.gov processed this record on May 19, 2013